Drugs / Sunobinop

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT06024642 Jun 2022 → May 2024 overactive bladder Imbrium Therapeutics Completed No outcome recorded
Phase 1 NCT06285214 May 2022 → Jan 2025 interstitial cystitis Imbrium Therapeutics Completed No outcome recorded
Phase 24 trials
Phase 2 NCT06545929 Jan → Jul 2025 alcohol-related disorders Knoa Pharma LLC Completed No outcome recorded
Phase 2 NCT06545916 Oct 2024 → May 2026 alcohol-related disorders Knoa Pharma LLC Completed No outcome recorded
Phase 2 NCT04035200 Sep 2019 → Nov 2020 insomnia Imbrium Therapeutics Completed No outcome recorded
Phase 2 NCT01900795 Jul → Nov 2013 Purdue Pharma LP Terminated No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Sunobinop ClinicalTrials.gov intervention name — accepted as the source's own label NCT06545929
1

NCT06545916

Known as IMB-115 ChEMBL registry synonym — accepted as the source's own label CHEMBL5095040
Known as IMB-115 tosylate ChEMBL registry synonym — accepted as the source's own label CHEMBL5095040
Known as RSC-117957 ChEMBL registry synonym — accepted as the source's own label CHEMBL5095040
Known as RSC-117957 TOSYLATE ChEMBL registry synonym — accepted as the source's own label CHEMBL5095040
Known as SUNOBINOP TOSYLATE ChEMBL registry synonym — accepted as the source's own label CHEMBL5095040
Known as V-117957 TOSYLATE ChEMBL registry synonym — accepted as the source's own label CHEMBL5095040
Known as V117957 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06285214
3

NCT04035200

NCT06024642

NCT01900795

Modality Small molecule CHEMBL5095040
Route Oral “taken orally after surgery.” NCT01900795